Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AIM
stocks logo

AIM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.980
-90.2%
0.00
-100%
-1.130
-77.4%
0.00
-100%
-1.130
-69.29%
Estimates Revision
The market is revising Upward the revenue expectations for AIM ImmunoTech Inc. (AIM) for FY2025, with the revenue forecasts being adjusted by 71.95% over the past three months. During the same period, the stock price has changed by -40.73%.
Revenue Estimates for FY2025
Revise Upward
up Image
+71.95%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-40.73%
In Past 3 Month
Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 15.00 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 15.00 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.470
sliders
Low
6.00
Averages
15.00
High
24.00
Current: 1.470
sliders
Low
6.00
Averages
15.00
High
24.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$5 → $4.5
2024-12-10
Reason
Ascendiant Capital
Edward Woo
Price Target
$5 → $4.5
2024-12-10
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AIM ImmunoTech Inc (AIM.A) is -0.34, compared to its 5-year average forward P/E of -2.17. For a more detailed relative valuation and DCF analysis to assess AIM ImmunoTech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.17
Current PE
-0.34
Overvalued PE
-0.15
Undervalued PE
-4.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
237.79
Current PS
0.00
Overvalued PS
446.77
Undervalued PS
28.80
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AIM News & Events

Events Timeline

(ET)
2025-12-02
09:11:00
Alpha Tau Receives FDA Approval for Prostate Cancer Study Using Alpha DaRT Technology
select
2025-11-18 (ET)
2025-11-18
09:37:04
AIM ImmunoTech Announces Q3 Earnings Per Share of $1.57 Compared to a Loss of $6.00 Last Year
select
2025-11-10 (ET)
2025-11-10
08:59:26
AIM ImmunoTech Provides Insights on UPMC Abstract Regarding Finished Ampligen Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-03Globenewswire
AI-Media Launches ADA Compliance Initiative to Aid Government Digital Accessibility
  • Compliance Initiative Launch: AI-Media has launched a comprehensive ADA Title II Compliance Initiative aimed at assisting state and local governments across the U.S. in meeting the newly finalized federal digital accessibility requirements, impacting public entities serving over 50,000 people.
  • Technological Support: The initiative includes the release of a 10-Point ADA Compliance Checklist and introduces two flagship technologies, LEXI Text for AI-powered captioning and transcription, and LEXI AD for audio description, ensuring compliance with WCAG 2.1 AA standards.
  • Educational Initiative: AI-Media will host a national webinar on January 20, 2026, titled “ADA Title II: Compliance Made Simple with AI,” aimed at raising awareness of accessibility requirements and demonstrating how AI technologies can facilitate compliance.
  • Market Demand: As the ADA Title II compliance deadlines approach, public entities are urgently seeking scalable and cost-effective solutions, and AI-Media's technologies are well-positioned to meet this demand by enabling accessible digital services for government agencies.
[object Object]
Preview
9.5
11-18Newsfilter
AIM ImmunoTech Announces Q3 2025 Financial Results and Ongoing Advancements in Pipeline with Emphasis on Pancreatic Cancer Clinical Initiatives

  • Business Update: AIM ImmunoTech reported positive clinical progress in its third quarter 2025, focusing on the development of Ampligen for pancreatic cancer in combination with AstraZeneca's Imfinzi, with a year-end update expected soon.

  • Recent Highlights: The company announced a European patent for treating Long COVID, presented clinical data at major conferences, and published a peer-reviewed article demonstrating the efficacy of Ampligen in cancer treatment.

  • Financial Overview: AIM reported $2.4 million in cash and investments as of September 30, 2025, with reduced research and administrative expenses compared to the previous year, resulting in a net loss of approximately $3.3 million.

  • Forward-Looking Statements: The company cautioned that its future success is uncertain and dependent on various risks, urging investors to consider potential risks outlined in their SEC filings.

[object Object]
Preview
9.0
11-10Newsfilter
AIM ImmunoTech Unveils New UPMC Abstract on Finished Clinical Trial Highlighting Ampligen's Synergistic Effects in Treating Advanced Recurrent Ovarian Cancer

  • Clinical Study Results: AIM ImmunoTech presented data from a Phase 2 clinical study on Ampligen for advanced recurrent ovarian cancer, showing a 50% objective response rate among evaluable patients, significantly higher than previous studies with pembrolizumab alone.

  • Synergistic Potential: The study supports AIM's belief that Ampligen can enhance the effectiveness of checkpoint inhibitors, potentially benefiting patients with refractory cancers that do not respond to standard treatments.

  • Expert Endorsement: Dr. Robert Edwards highlighted Ampligen's potential to improve tumor immune responses and extend remission periods for patients with limited treatment options.

  • Company Overview: AIM ImmunoTech focuses on developing therapeutics for various cancers and diseases, with Ampligen as its lead investigational drug, and holds multiple patents for its combination therapy approaches.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AIM ImmunoTech Inc (AIM) stock price today?

The current price of AIM is 1.47 USD — it has increased 5 % in the last trading day.

arrow icon

What is AIM ImmunoTech Inc (AIM)'s business?

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

arrow icon

What is the price predicton of AIM Stock?

Wall Street analysts forecast AIM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIM is 15.00 USD with a low forecast of 6.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AIM ImmunoTech Inc (AIM)'s revenue for the last quarter?

AIM ImmunoTech Inc revenue for the last quarter amounts to 26.00K USD, decreased -25.71 % YoY.

arrow icon

What is AIM ImmunoTech Inc (AIM)'s earnings per share (EPS) for the last quarter?

AIM ImmunoTech Inc. EPS for the last quarter amounts to -1.57 USD, decreased -75.55 % YoY.

arrow icon

What changes have occurred in the market's expectations for AIM ImmunoTech Inc (AIM)'s fundamentals?

The market is revising Upward the revenue expectations for AIM ImmunoTech Inc. (AIM) for FY2025, with the revenue forecasts being adjusted by 71.95% over the past three months. During the same period, the stock price has changed by -40.73%.
arrow icon

How many employees does AIM ImmunoTech Inc (AIM). have?

AIM ImmunoTech Inc (AIM) has 21 emplpoyees as of December 05 2025.

arrow icon

What is AIM ImmunoTech Inc (AIM) market cap?

Today AIM has the market capitalization of 3.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free